Literature DB >> 33590767

Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.

Huiqun Wang1, Danni Cao2, James C Gillespie3, Rolando E Mendez3, Dana E Selley3, Lee-Yuan Liu-Chen2, Yan Zhang1.   

Abstract

The modulation and selectivity mechanisms of seven mixed-action kappa opioid receptor (KOR)/mu opioid receptor (MOR) bitopic modulators were explored. Molecular modeling results indicated that the 'message' moiety of seven bitopic modulators shared the same binding mode with the orthosteric site of the KOR and MOR, whereas the 'address' moiety bound with different subdomains of the allosteric site of the KOR and MOR. The 'address' moiety of seven bitopic modulators bound to different subdomains of the allosteric site of the KOR and MOR may exhibit distinguishable allosteric modulations to the binding affinity and/or efficacy of the 'message' moiety. Moreover, the 3-hydroxy group on the phenolic moiety of the seven bitopic modulators induced selectivity to the KOR over the MOR.

Entities:  

Keywords:  allosteric modulation mechanism; kappa opioid receptor (KOR)/mu opioid receptor (MOR); mixed-action KOR/MOR ligand; molecular dynamics simulations; psychostimulant abuse and addiction; selectivity

Mesh:

Substances:

Year:  2021        PMID: 33590767      PMCID: PMC8027703          DOI: 10.4155/fmc-2020-0308

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  81 in total

1.  Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.

Authors:  S W Tam; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  1986-11       Impact factor: 4.030

2.  Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.

Authors:  C Chen; J Yin; J K Riel; R L DesJarlais; L F Raveglia; J Zhu; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

3.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

4.  CHARMM-GUI Membrane Builder for mixed bilayers and its application to yeast membranes.

Authors:  Sunhwan Jo; Joseph B Lim; Jeffery B Klauda; Wonpil Im
Journal:  Biophys J       Date:  2009-07-08       Impact factor: 4.033

Review 5.  Neuropathological alterations in cocaine abuse.

Authors:  A Büttner
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 6.  Computational approaches to mapping allosteric pathways.

Authors:  Victoria A Feher; Jacob D Durrant; Adam T Van Wart; Rommie E Amaro
Journal:  Curr Opin Struct Biol       Date:  2014-03-22       Impact factor: 6.809

7.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Authors:  Bryan L Roth; Karen Baner; Richard Westkaemper; Daniel Siebert; Kenner C Rice; SeAnna Steinberg; Paul Ernsberger; Richard B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

8.  Orvinols with mixed kappa/mu opioid receptor agonist activity.

Authors:  Benjamin M Greedy; Faye Bradbury; Mark P Thomas; Konstantinos Grivas; Gerta Cami-Kobeci; Ashley Archambeau; Kelly Bosse; Mary J Clark; Mario Aceto; John W Lewis; John R Traynor; Stephen M Husbands
Journal:  J Med Chem       Date:  2013-04-03       Impact factor: 7.446

Review 9.  Allosteric Modulation of Chemoattractant Receptors.

Authors:  Marcello Allegretti; Maria Candida Cesta; Massimo Locati
Journal:  Front Immunol       Date:  2016-05-02       Impact factor: 7.561

10.  Structure of the µ-opioid receptor-Gi protein complex.

Authors:  Antoine Koehl; Hongli Hu; Shoji Maeda; Yan Zhang; Qianhui Qu; Joseph M Paggi; Naomi R Latorraca; Daniel Hilger; Roger Dawson; Hugues Matile; Gebhard F X Schertler; Sebastien Granier; William I Weis; Ron O Dror; Aashish Manglik; Georgios Skiniotis; Brian K Kobilka
Journal:  Nature       Date:  2018-06-13       Impact factor: 49.962

View more
  1 in total

Review 1.  Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction.

Authors:  Robert Root-Bernstein
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.